Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today...
ISX Financial EU Plc Announces Corporate Name Change to Xryma Plc
NICOSIA, Cyprus, March 24, 2026 /PRNewswire/ -- ISX Financial EU Plc, an EEA-authorised Electronic Money Institution (EMI) authorised by the Central Bank of Cyprus, announced that its shareholders have approved the change of the company's name to...
Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Second Quarter of Fiscal 2026 Ended December 31, 2025
SHANGHAI, March 23, 2026 /PRNewswire/ -- Gamehaus Holdings Inc. ("Gamehaus" or the "Company") (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced its unaudited financial results for the second quarter of fiscal year 2026 ended...
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
RyzoBee Announces Root Series Kickstarter Launch Planned for Q2 2026, Bringing Modular RootMaker Electronics to Makers and 3D Printing Creators in North America and Europe
HONG KONG, March 21, 2026 /PRNewswire/ -- RyzoBee today announced that its Root Series is planned to launch on Kickstarter in Q2 2026 for the North American and European markets (timing subject to confirmation). In response to growing...
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon2
Treatment with ZEGFROVY ® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful...
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
Full-Year Revenue Growth of 867.9% Year-over-Year Achieved Net Income Turnaround in Fiscal Year 2025 HONG KONG, March 21, 2026 /PRNewswire/ -- FiEE, Inc. (NASDAQ:FIEE) ("FiEE" or the "Company"), a technology company integrating IoT, connectivity and...
Ten Pao Group Announces 2025 Annual Results
Revenue Increased 3.2% to HK$5,558.6 million, with Rising Dividend Payout to 34.7% Industrial and Consumer Power Supply Businesses Recorded Solid Growth, Supported by Expanding Global Manufacturing Capabilities Financial highlights For the year...
Everbright Environment Announces 2025 Annual Results
HONG KONG, March 20, 2026 /PRNewswire/ -- China Everbright Environment Group Limited ("Everbright Environment" or the "Company") (257.HK) announces the consolidated results of the Company and its subsidiaries (collectively the "Group") for the year...
CNOOC Limited Announces Huang Yongzhang as Chief Executive Officer
HONG KONG, March 20, 2026 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that Mr. Huang Yongzhang has been appointed as the Vice Chairman, an Executive Director, the...